Cytostatic and cytotoxic properties of amphinase: A novel cytotoxic ribonuclease from Rana pipiens oocytes

Cell Cycle

Volumn 6, Issue 24, 2007, Pages 3097-3102

  Ardelt, Barbara ^a,b   Ardelt, Wojciech ^b   Pozarowski, Piotr ^a,c   Kunicki, Jan ^a   Shogen, Kuslima ^b   Darzynkiewicz, Zbigniew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Alfacell Research Laboratories   (United States)

^c School of Medicine   (Poland)

Author keywords

Anti cancer properties; Apoptosis; Caspase activation; Cell cycle; Cytotoxic ribonuclease; G1 arrest; Onconase; Ranpirnase; Serine protease activation; Transglutaminase activation

Indexed keywords

AMPHINASE; AMPHINASE 1; AMPHINASE 2; AMPHINASE 3; AMPHINASE 4; CASPASE; HISTIDINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RANPIRNASE; RIBONUCLEASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; FROG; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOLECULAR WEIGHT; NICK END LABELING; OOCYTE; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH;

AMPHIBIA; RANA PIPIENS;

EID: 38149109693     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.24.5045     Document Type: Article

References (51)

1. Leland PA, Raines RT. Cancer chemotherapy - Ribonucleases to the rescue. Chem Biol 2001; 8:405-13.
2. Matoušek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol 2001; 129C:175-91.
3. Benito A, Ribó M, Vilanova M. On the track of antitumour ribonucleases. Mol Biosyst 2005; 1:294-302.
4. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for Ranpirnase. Cancer Invest 2005; 23:643-50.
5. Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006; 28:1615-22.
6. Lee JE, Raines RT. Ribonucleases as novel chemotherapeutics: The ranpirnase example. BioDrugs 2007, (in press).
7. Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem 1991; 266:245-51.
8. Mosimann SC, Ardelt W, James MNG. Refined 1.7 Å X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol 1994; 236:1141-53.
9. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effect of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988; 21:169-82.
10. Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. A cytotoxic ribonuclease: Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993; 268:10686-93.
11. KIP and decreased pRb phosphorylation. Leukemia 1998; 12:1241-8.
12. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990; 82:151-3.
13. Lee I, Lee YH, Mikulski SM, Shogen K. Effect of ONCONASE +/- tamoxifen on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol 2003; 530:187-96.
14. Lee I, Kalota A, Gewirtz AM, Shogen K. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 2007; 27:299-307.
15. Mikulski SM, Viera A, Ardelt W, Menduke H, Shogen K. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 1990; 23:237-46.
16. Mikulski SM, Viera A, Darzynkiewicz Z, Shogen K. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects inhuman lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66:304-10.
17. Deptala A, Halicka HD, Ardelt B, Ardelt W, Mikulski SM, Shogen K, Darzynkiewicz Z. Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 1998; 13:11-6.
18. Halicka HD, Murakami T, Papageorgio CN, Mittelman A, Mikulski SM, Shogen K, Darzynkiewicz Z. Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. Cell Prolif 2000; 33:407-17.
19. Halicka HD, Ardelt B, Shogen K, Darzynkiewicz Z. Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase. Int J Oncol 2007; 30:841-7.
20. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro- apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005; 23:643-50.
21. Pavlakis N, Vogelzang NJ. Ranpirnase-an antitumour ribonuclease: Its potential role in malignant mesothelioma. Expert Opin Biol Ther 2006; 6:391-9.
22. th International Conference on Ribonucleases, L-27, 2002:19-23.
23. Singh UP, Ardelt W, Saxena SK, Holloway DE, Vidunas E, Lee HS, Saxena A, Shogen K, Acharya KR. Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens Oocytes. J Mol Biol 2007, (Epub).
24. Crestfield AM, Stein WH, Moore S. Alkylation and identification of the histidine residues at the active site of ribonuclease. J Biol Chem 1963; 238:2413-20.
25. 1" peaks on DNA content histograms. Cytometry A 2007; 71A:125-31.
26. Gorczyca W, Bruno S, Darzynkiewicz RJ, Gong J, Darzynkiewicz Z. DNA strand breaks occurring during apoptosis: Their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Onc 1992; 1:639-48.
27. Grabarek J, Du L, Johnson GL, Lee B, Phelps DJ, Darzynkiewicz Z. Sequential activation caspases and serine proteases (serpases) during apoptosis. Cell Cycle 2002; 1:124-31.
28. Grabarek J, Ardelt B, Du L, Darzynkiewicz Z. Activation of caspases and serine proteases during apoptosis induced by onconase (Ranpirnase). Exp Cell Res 2002; 278:61-71.
29. Grabarek J, Ardelt B, Kunicki J, Darzynkiewicz Z. Detection of in situ activation of transglutaminase during apoptosis: Correlation with the cell cycle phase by multiparameter flow- and laser scanning- cytometry. Cytometry 2002; 49:83-89.
30. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27:1-20.
31. Pozarowski P, Huang X, Halicka DH, Lee B, Johnson G, Darzynkiewicz Z. Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: A caution in data interpretation. Cytometry 2003; 55A:50-60.
32. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993; 53:1945-51.
33. Ardelt B, Ardelt W, Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2003; 2:22-4.
34. Mattick JS. A new paradigm for developmental biology. J Exp Biol 2007:210:1526-47.
35. Mattick JS, Makunin IV. Noncoding RNA. Hum Mol Genet 2006; 15(Spec No1): R17-29.
36. Mattick JS. RNA regulation: A new genetics. Nat Rev Genet 2004; 5:316-23.
37. Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006; 33:163-173.
38. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yunaihara N, Lanza G, Scarpa A, Veccione A, Negrini M, Harris CC, Croce CM. A microRNAs expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61.
39. Hernando E. microRNAs and cancer: Role in tumorigenesis, patient classification and therapy. Clin Transl Oncol 2007; 9:155-60.
40. 1-arrest. Cell Cycle 2007; 13:1586-93.
41. Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: A paradigm for RNA-mediated regulation of gene expression. Bioessays 2002; 24:119-29.
42. Mishima Y, Giraldez AJ, Takeda Y, Fujiwara T, Sakamoto H, Schier AF, Inoue K. Differential regulation of germline mRNAs in soma and germ cells by zebrafish miR-430. Curr Biol 2006; 16:2135-42.
43. Song L, Tuan RS. MicroRNAs and cell differentiation in mammalian development. Birth Defects Res C Embryo Today 2006; 78:140-9.
44. Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005; 280:9330-5.
45. Looijenga LHJ, Gillis AJM, Stoop H, Hersmus R, Oosterhuis JW. Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumors. Int J Androl 2007; 30:304-15.
46. Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003; 116:313-24.
47. Rodriguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF, Ribó M, Benito A, Vilanova M, Beaumelle B. Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 2007; 120:1405-11.
48. James AM, Ambrose EJ, Lowick JH. Differences between the electrical charge carried by normal and homologous tumour cells. Nature 1956; 177:576-7.
49. Márquez M, Nilsson S, Lennartsson L, Liu Z, Tammela T, Raitanen M, Holmberg AR. Charge-dependent targeting: Results in six tumor cell lines. Anticancer Res 2004; 24:1347-51.
50. Carter HB, Partin AW, Coffey DS. Prediction of metastatic potential in an animal model of prostate cancer: Flow cytometric quantification of cell surface charge. J Urol 1989; 142:13338-48.
51. Ilinskaya ON, Zelenikhin PV, Petrushanko IY, Mitkevich VA, Prassolov VS, Makarov AA. Binase introduces apoptosis of transformed myeloid cells and does not induce T-cell immune response. Biochem Biophys Res Commun 2007; In press.